

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>A61K 9/40, 9/14, 9/48, 9/52, 9/62</b>		<b>A1</b>	(11) International Publication Number: <b>WO 98/50019</b>
			(43) International Publication Date: 12 November 1998 (12.11.98)
(21) International Application Number: <b>PCT/US98/09449</b>			(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 8 May 1998 (08.05.98)			
(30) Priority Data: 60/046,089 9 May 1997 (09.05.97) US 08/950,432 15 October 1997 (15.10.97) US			
(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Applications US 60/046,089 (CIP) Filed on 9 May 1997 (09.05.97) US 08/950,432 (CIP) Filed on 15 October 1997 (15.10.97)			
(71) Applicant (for all designated States except US): SAGE PHARMACEUTICALS, INC. [US/US]; 5408 Interstate Avenue, Shreveport, LA 71109 (US).			
(72) Inventor; and (75) Inventor/Applicant (for US only): CHEN, Jivn-Ren [US/US]; 7614 Brook Haven Way, Shreveport, LA 71105 (US).			Published With international search report.
(74) Agent: CHAN, Albert, Wai-Kit; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).			
(54) Title: STABLE ORAL PHARMACEUTICAL DOSAGE FORMS			
(57) Abstract  The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage form, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.			

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

STABLE ORAL PHARMACEUTICAL DOSAGE FORMS

5 This application is a continuation-in-part application of  
U.S. Serial No. 08/950,432, filed October 15, 1997,  
claiming priority of U.S. Provisional Application No.  
60/046,089, filed May 9, 1997, the content of which is  
incorporated by reference into this application.

Background of the Invention

10

U.S. patent number 4,255,431 describes a compound  
2-[2-(3,5-dimethyl -4-methoxy)-pyridyl methyl sulfinyl]-  
(5-methoxy)-benzimidazole (Omeprazole) or pharmaceutically  
acceptable salt or non-toxic acid addition salt as a  
15 therapeutic compound for mammals including man, suffering  
from gastric acid secretion disturbances.

Omeprazole, however is only stable in basic pH conditions  
and degrades rapidly in neutral or acid pH environment.  
20 For this reason the omeprazole oral dosage form must be  
protected, not only from the acidic inert ingredients used  
to make a dosage form but also from the acidic gastric  
fluid in order to intactly reach the absorption site in the  
small intestine.

25

A study [Drug Dev. Ind. Pharm. 21(8), 965 (1995)] showed  
the effect of pH on the stability of omeprazole solution.  
The pH-decomposition rate profile curve indicated that the  
maximum stability was at pH 11. Below pH 7.8 the  
30 decomposition was very fast.

A survey of the stability of Omeprazole products from 13  
countries was reported [Drug Dev. Ind. Pharm. 22(12),  
1173(1996)]. The results of this independent survey of the  
35 stability of omeprazole solid dosage forms (20 mg) show  
that product available in many countries worldwide exhibits  
a very wide range of stability characteristics. Only 18% of

-2-

total products tested (34) were considered to demonstrate good physical and chemical stability over the course of the study.

5 U.S. patent number 4,628,098 discloses that:

*Lansoprazole is a substituted benzimidazole 2-[[[3-methyl  
-4- (2,2,2- trifluoroethoxy)-2- pyridyl ] methyl ] sulfinyl  
] benzimidazole, a compound and a pharmacologically  
10 acceptable salt thereof that inhibits gastric acid  
secretion.*

Lansoprazole is relatively stable when exposed to light. The compound degrades in aqueous solution, the rate of degradation increasing with decreasing pH.

15

It is well known in the pharmaceutical industry that an enteric coating technology is the most efficient means to protect acid unstable medication from the attack of the gastric fluid and can rapidly release the active drug in  
20 the proximal part of the gastrointestinal canal.

An enteric coated dosage form of omeprazole was reported in 1985 by Pilbrant and Cederberg (Scand. J. Gastroenterology 1985; 20 (supp.108) p. 113 - 120). It was found later that  
25 the stability of this dosage form was not sufficient for a long term commercial purpose.

Because of the acidic property of the enteric coating polymer, the omeprazole or lansoprazole will degrade and  
30 diminish its therapeutic value by direct or indirect contact with it during or after the coating process, even in the presence of alkaline inert ingredients with the active drug in the core particles.

35 DE - AI number 3046 559 teaches a two layer coating system for a dosage form in which the first coating is a water insoluble layer of microcrystalline cellulose and then

-3-

enteric coating as the second layer to release the active drug in the colon.

5 WO number 85/03436 describes a technique to mix active drug with buffering components (i.e. sodium dihydrogen phosphate) to maintain a constant pH in a core for particular purposes. The core is coated with a layer which controls the diffusions.

10 All of these inventions when applied to omeprazole's or lansoprazole's case will not give either an adequate release of active drug or storage stability of such dosage form.

15 U.S. patent number 4,786,505 teaches an art to make an oral pharmaceutical preparation comprising (1) a core consisting of omeprazole plus an alkaline reacting compound (2) an inert subcoating of core (3) an enteric coating of subcoated core and to use it in the treatment of  
20 gastrointestinal disease.

This technique requires a series of cumbersome and laborious pharmaceutical processes: 1) preparation of the core, which should be suitable for multilayer coating 2)  
25 Coating the core with one or more layers of an inert subcoating containing one or more alkaline substances 3) applying an outer enteric coating to the subcoated core 4) make the pharmaceutical preparation for therapeutical use.

30 U.S. patent number 5,232,706 claims an oral pharmaceutical preparation of omeprazole or an alkali salt of omeprazole and a process for producing such preparation. The design principle of the preparation is basically similar to the U.S. patent number 4,786.505. This preparation is  
35 comprised of: 1) a nucleus of active drug and first basic organic compound; 2) a first coating of nucleus containing at least a layer of a basic water soluble excipient and a

-4-

second basic organic compound; and 3) a second coating formed by an enteric coating.

5 The major difference between U.S. patent number 5,232,706 and U.S. patent number 4,786,505 is the type of basic compound used; the former uses basic organic compound the later uses inorganic alkaline reaction compounds in core and in subcoating.

10 U.S. patent number 5,385,739 relates to a stable formulation of Omeprazole microgranules containing a neutral core of sugar and starch coated with an active layer of drug and mannitol powder mixture with the aid of a solution of a binding agent in water plus ethanol. An  
15 additional protective layer of mannitol and sugar syrup is then applied prior to the final gastroprotection coating.

20 The art of coating a powder mixture containing an active ingredient onto the core of sugar and starch by using a binding solution is a rather difficult process to obtain uniform drug core granules.

25 In addition, two applications of aqueous solution involving the direct contact with Omeprazole, in the coating process, may effect the stability of this moisture-sensitive drug.

30 U.S. patent number 5,399,700 teaches a method for stabilizing an acid unstable benzimidazole derivative, by forming an inclusion complex of Omeprazole with cyclodextrin.

35 This inclusion complex was synthesized in an aqueous alkaline solution at 40° - 70°C and then used to manufacture a tablet which is first coated by a water soluble substance and then with an enteric substance to form an enteric coated oral drug.

-5-

5 The safety of cyclodextrin for human oral dosage form needs to be clarified. Even if the acid stability and dissolution characterization of this inclusion complex has been well demonstrated in vitro, its behavior in vivo is not referenced in this patent.

10 U.S. patent number 4,689,333 claims a pharmaceutical composition for preventing or treating digestive ulcers or gastritis which contains an effective amount of Lansoprazole or a pharmacologically acceptable salt thereof and pharmacologically acceptable carriers.

15 A study [Drug Dev. Ind. pharm. 18 (13), 1437 (1992)] reported that enteric granule formulations for Lansoprazole was established, however, it was difficult because some of the excipients needed for these formulations are incompatible with the drug. The alkaline stabilizers were then screened and the optimal pH stability of 9 was suggested in this paper.

20 A continued study from the above mentioned effort [Drug Dev. Ind. pharm. 20(9), 1661 (1994)] attempted to prepare more stable enteric granules without using these troublesome excipients by using a centrifugal fluid-bed granulator instead of an extruder-spheronizer. It was said that with this method more stable enteric granules could be obtained. The utilization of special sophisticated equipment to achieve the stable granules may suffer economical disadvantages.

30 U.S. patent number 5,026,560 discloses spherical granules having a seed core coated with a binder and spraying powder containing lansoprazole as active drug, low substituted hydroxypropylcellulose and magnesium or calcium carbonate as alkaline agents. The powder coated core is further  
35 coated with spraying powder of low substituted hydroxypropylcellulose and then with enteric coating agent.

-6-

Technically, powder coating in pharmaceutical manufacturing brings forth issues such as content uniformity of the active on the seed core, laborious process attention and time consumption. It therefore tremendously increases the cost of the product.

U.S. patent number 5,045,321 describes a pharmaceutical composition for coated tablets or granules, which is comprised of lansoprazole being in contact with at least one of the basic inorganic salts evenly. No protective and/or enteric coating is mentioned in the patent claim.

U.S. patent number 5,093,132 is similar to the U.S. patent number 5,045,321 but more specifically, describes an oral stabilized pharmaceutical composition for the inhibition of gastric acid secretion comprising of lansoprazole or its pharmaceutically acceptable salt in contact evenly with a basic inorganic salt stabilizing agent. It also mentions simply an enteric coating for the composition.

Enteric coated oral solid dosage forms have been in existence for a century. U.S. patent number 3,656,997 and 3,959,540 disclosed a coated gastric juice resistant capsules and process for the production thereof. Most commercially available products under this category are coated pellets or granule filled capsules and tablet dosage forms. The concept of an enteric coated capsule dosage for commercial purposes are relatively new. So far, only one prescription product - VIVOTIF BERNA™ (Berna Products, Co., Coral Gables, Fl.) is in the U.S.A. market.

The advantage of enteric coated capsules are duplex. In addition to the merit natures of enteric coating polymers, the problem involved and the need for extensive efforts in development and the preparation of enteric pellets or tablets can be avoided.



-7-

Historically, enteric coated hard shell capsules were manufactured with formaldehyde treatments. This technology results in a stability problem with this product. Since the successful introduction of a number of enteric polymeric materials, the technology of this coating becomes more popular and is increasingly used in the pharmaceutical industry. However, the use of organic solvents causes risks of air pollution and inflammability. With the advent and availability of aqueous enteric polymer dispersions, manufacturing of enteric coated dosage forms have acquired a great deal of attention. The modern coating equipment now offers to pharmaceutical manufacturers better conditions for the application of aqueous coatings.

The process of enteric coating for pharmaceutical dosage forms are not significantly different with other coating processes. Generally, the sample is first placed in the coating pan or in the fluid-bed chamber for fluidization, while a coating solution is then spraying through a gun according to the two operations: 1) spraying or wetting and 2) drying, which is repeated consecutively during the process.

-8-

Summary of the Invention

5 It is well known that the stability of omeprazole and lansoprazole may be affected adversely in the presence of water and organic solvent, especially by the former.

10 The previous art of U.S. patent number 4,786,505 and number 5,232,706 all use conventional aqueous wet technologies to make core pellets or granulations. This invention, by preferably using dry mixing of drugs with alkaline substances as core granulations for either capsule filling or direct tablet compression in its processes, can substantially eliminate the stability risk of the active by excluding the moisture from the core granulation.

15 The alkaline substances in contact with the enteric coating in the aqueous environment can reduce the acid resistance properties of the latter. The invention of the above mentioned two U.S. patents includes the alkaline substances in the subcoating which is directly in contact with the enteric coating, thus it could be detrimental to the gastric fluid resistance of the enteric coating and result in the inferior therapeutic efficacy of omeprazole or lansoprazole.

25 For this reason the present invention uses a capsule shell as a separating barrier between the alkaline core of active drug and the enteric coatings. In the case of a tablet, only the pure, non-ionic polymer is used as a protective coating.

30

35 Furthermore, the present invention describes an improved oral pharmaceutical dosage form for omeprazole, its salt, lansoprazole or its salts. It is comprised of 1) a core powder or granules of active drug and alkaline inorganic or organic substances is formed by dry mixing; 2) said powder or granulation is filled into a hard gelatin capsule or is

- 9 -

5 further mixed with other pharmaceutical excipients for direct tablet compression; 3) (for tablet only) a conventional pharmaceutical protective coating is disposed on the tablets; and 4) an outer layer of enteric coating is disposed on the dosage form (capsule or tablet).

10 This improved dosage form is more economically feasible in terms of time process and material savings. It is sufficiently stable for commercial distribution and storage. It also effectively protects the active drug from the attack of the acidic gastric fluid and efficiently delivers the active drug to the small intestine.

15 A process for the manufacturing of an oral dosage form of omeprazole or lansoprazole was also described. The details of granulation, encapsulation, tableting and coating art can be found in "The Theory and Practice of Industrial Pharmacy, 1986, Lea & Febiger, Philadelphia, PA, USA, the content of which is incorporated into this application as  
20 a reference.

Detailed Description of the Invention

5 This is an invention of an improved pharmaceutical dosage  
form for oral administration to human being or animal host  
which is comprised of: (a) a core granulation formed by dry  
mixing an acid-unstable drug or its salt and an alkaline  
substance or pharmaceutical excipient without using an  
aqueous granulating solution; (b) said dry core granulation  
can then be quantitatively filled into a proper size empty  
10 hard gelatin capsule shell using this shell as a barrier  
and hence eliminating the process of applying a protective  
coating layer onto the granulation. In other words, this  
hard gelatin capsule shell constitutes simultaneously a  
barrier between said core granulation and the outer enteric  
15 coating of said capsule during the processing to complete  
the capsule dosage form; and (c) an enteric coating can  
then be applied onto said capsule to prevent the capsule  
from releasing the acid-unstable drug in a low pH  
environment (i.e. stomach) and then to deliver the drug in  
20 a higher pH environment (i.e. small intestine).

25 As used herein, core granulation is a mixture of a  
pharmaceutically acceptable granulated alkaline substance  
and, or excipient, and a drug active ingredient that can be  
processed into uniform spherelike or regularly shaped  
aggregates for the improvement of flowability and  
compressibility. The manufacturing processes may employ  
one, or a combination of, four established methods:

- 30 1) dry mixing;  
2) direct compression;  
3) milling; and  
4) non-aqueous granulation.

35

These methods are described in "The Theory and Practice of  
Industrial Pharmacy, 1986, Lea & Febiger, Philadelphia, PA,

-11-

USA, edited by Lachman, L., Lieberman, H.A., and Kanig, J.L.

5 This invention also includes an improved pharmaceutical dosage form for oral administration to human being or animal host which consists of: (a) a core granulation formed by dry mixing an acid-unstable drug or its salt, and an alkaline substance or pharmaceutical excipient, without using an aqueous granulating solution, and which can be  
10 directly compressed into a tablet; (b) said tablet can then be filled into an empty, hard gelatin capsule shell using this shell as a barrier and hence eliminating the process of applying a protective layer onto the tablet. In other words, this hard gelatin capsule shell constitutes  
15 simultaneously a barrier between the said tablet and an outer enteric coating of said capsule during the processing to complete the capsule dosage form; and (c) an enteric coating can then be applied onto said capsule to prevent the capsule from releasing the acid-unstable drug in the  
20 low pH environment (i.e. stomach) and then to deliver the drug in a higher pH environment (i.e. small intestine).

Also included in this invention is an improved pharmaceutical dosage form for oral administration to human  
25 being or animal host which consists of: (a) a core granulation formed by dry mixing an acid-unstable drug or its salt, and an alkaline substance or pharmaceutical excipient, without using an aqueous granulating solution, which can then be directly compressed into a tablet; (b)  
30 said tablet can then be coated with a non-ionic protective coating in an organic solvent as a barrier: (1) to separate the acid-unstable active drug in the tablet from the outer enteric coating and, (2) to protect the outer enteric coating from the permeation of generated alkaline solution  
35 formed by any existed water in the core tablet; and (c) an enteric coating then can be applied onto said tablet to protect it from releasing the acid-unstable drug in a low

-12-

pH environment (i.e. the stomach) and to deliver the active in a higher pH environment (i.e. the small intestine).

5 The protective coating can be applied by a standard film coating procedure in a suitable coating machine using a non-aqueous solution. The non-ionic protective polymer is selected from the group consisting of hydroxypropyl methylcellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, and polyvinylpyrrolidone. The organic solvent  
10 is selected from the group consisting of isopropyl alcohol, methanol and ethanol. Other appropriate non-ionic protective polymer may be similarly used.

15 The plasticizer for protective coating includes, but is not limited to, triethyl citrate, propylene glycol and polyethylene glycol 6000.

20 In a preferred embodiment, the drug active ingredient comprises Omeprazole, salt of Omeprazole - selected from the group consisting of sodium, potassium, calcium and ammonium salts, Lansoprazole or salt of Lansoprazole.

25 In another embodiment, the alkaline substance of dosage form mentioned above comprises one or any combination of the following: (a) alkaline metallic salt of carbonic acid: calcium carbonate, granulated calcium carbonate; (b) dicalcium phosphate anhydrous, Dibasic sodium phosphate anhydrous, tricalcium phosphate, anhydrous; (c) sodium carboxymethylcellulose, calcium carboxymethylcellulose; (d)  
30 magnesium aluminum silicate; (e) sodium lauryl sulfate; (f) sodium bicarbonate; and (g) microcrystalline cellulose, hydroxypropylmethylcellulose, hydroxyethylcellulose.

35 Also in another embodiment, the pharmaceutical excipient mentioned in the above dosage forms may be selected from one or any combination of the group consisting of dextrose, sorbitol, mannitol, starch, dextrin, maltodextrin, lactose,

-13-

magnesium stearate, calcium stearate, talc, microcrystalline cellulose, hydroxypropylmethylcellulose and hydroxyethylcellulose.

5 Also in another embodiment, the pharmaceutical excipient mentioned in the above dosage forms may be selected from one or any combination of the group consisting of dextrose, sorbitol, mannitol, starch, dextrin, maltodextrin, lactose, magnesium stearate, calcium stearate, talc,  
10 microcrystalline cellulose, hydroxypropylmethylcellulose and hydroxyethylcellulose. Other appropriate excipients may be similarly used.

In a separate embodiment, the enteric coating comprises:  
15 (a) cellulose acetate phthalate, (C-A-P) cellulose acetate trimellitate (C-A-T), Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS), Hydroxypropyl Methylcellulose phthalate (HPMCP), polyvinyl acetate phthalate (PVAP), Anionic phthalate polymers based on methacrylic acid and  
20 methacrylic acid esters; (b) compounds either alone or in any combination in organic solvent, (i.e isopropyl alcohol, methanol, ethanol or ethyl acetate) containing at least one plasticizer (i.e. triethyl citrate, polyethylene glycol 6000 or glycerol monostearate, as a coating solution; (c)  
25 the group of compounds in (a) either alone or in any combination in aqueous dispersion containing at least one plasticizer can be an alternative coating solution; and (d) the process to apply the coating solution or dispersion to said capsules or tablets is a conventional pharmaceutical  
30 method. The coating procedures are performed in a suitable coating machine.

This invention provides a process for manufacturing the capsule dosage form of above described drug which comprises  
35 steps of: (a) preparing the granulation by preferably dry mixing the active ingredient and alkaline substance(s) or by non-aqueous wet granulation method using only the

-14-

pharmaceutically acceptable organic solvent, preferably methanol, ethanol or isopropyl alcohol as wetting solution and drying the granulation; (b) filling the capsule with the dried granulation; and (c) coating the capsules with an enteric coating solution or dispersion solution described above.

This invention provides a aqueous-free process for manufacturing the tablet dosage form that comprises steps of (a) preparing the granulation by preferably dry mixing the active ingredient and alkaline substance or pharmaceutical excipients; (b) directly compressing the granulation into a tablet by a conventional method; (c) filling the tablet into an empty hard gelatin capsule shell and; (d) coating the capsule with an enteric coating.

This invention provides an improved pharmaceutical dosage form for oral administration to human being or animal host containing an acid-unstable drug active ingredient which comprises: (a) a core tablet formed by dry mixing drug or its salt with alkaline substance and pharmaceutical excipient or excipients and directly compressing, which can be coated with a protective layer as a barrier to: (i) separate the acid-unstable active drug in the core from the outer enteric coating; and (ii) protect the entered coating from the permeation of alkaline solution formed by water in the core tablet; and (b) an enteric coating disposed on said protectively coated tablet to protect it from releasing the acid-unstable drug in the stomach and to deliver the active to the small intestine. In an embodiment of the above process for manufacturing the improved pharmaceutical dosage form, the core granulation is prepared by dry mixing, direct tablet compressing, subcoating the tablet with organic solvent base protective coating; and coating the subcoated tablets with an enteric coating solution or dispersion.



-15-

This invention provides an improved pharmaceutical dosage form for oral administration to human being or animal host containing an acid-unstable drug active ingredient which comprises: (a) a core tablet formed by dry mixing drug or its salt with alkaline substance and pharmaceutical excipient or excipients and directly compressing, which can then be coated with a protective layer as a barrier to: (i) separate the acid-unstable active drug in the core from the outer enteric coating; and (ii) protect the enteric coating from the permeation of alkaline solution formed by water in the core tablet; (b) an enteric coating disposed on said protectively coated tablet to prevent it from releasing the acid-unstable drug in the stomach and to deliver the active to the small intestine; and (c) this tablet is then filled into an empty hard gelatine capsule shell to form a final dosage form. In an embodiment of the above process for manufacturing the improved pharmaceutical dosage form, the core granulation is prepared by dry mixing, direct tablet compressing, subcoating the tablet with organic solvent base protective coating, coating the subcoated tablets with an enteric coating solution or dispersion and filling the said enteric coated tablet into an empty hard gelatin capsule.

Example 1.

Core Granulations: Non-Aqueous Wet Granulation:

- A. Ten grams of Omeprazole were granulated with 10 ml. of ethyl alcohol with agitation. The moist granules were dried and screened to obtain a uniform granule size.
- B. A suspension of Omeprazole being 10 grams in 50 ml. of ethyl alcohol was added into 100 grams of an alkaline inert compound being calcium carbonate granules (DELAVAL, Philadelphia, PA) with agitation to mix homogeneously the liquid and solids. The moist

-16-

granules were dried and screened for uniform and adequate granule size.

- 5 C. Same as Example 1.B., except the alkaline substance is calcium carbonate 90A (Particle Dynamics, Inc., St. Louis, MO.)
- 10 D. A mixture of 16 grams of Omeprazole and 10 grams of povidone USP was dispersed in 15 ml. of ethyl alcohol. The rest of the procedure is same as Example 1.B. above except that the dispersion was used to replace the suspension for 84 grams of alkaline substance.
- 15 E. Ten grams of sodium carboxymethylcellulose was dispersed in 10 ml. of ethyl alcohol. This liquid was then used to granulate a mixture of 2 grams of Omeprazole and 5 grams of calcium carbonate 90A (same as that used in Example 1.C.). The remaining portion of the procedure is the same as Example 1.B. above.

20

### Example 2.

#### Core Granulation: Dry Mixing:

25

- A. Ten grams of Omeprazole were mixed with an alkaline substance being tricalcium phosphate anhydrous USP/NF and then passed through a screen to obtain a homogenous granule size.
- 30 B. Same as Example 2.A. above except the alkaline substance is pharmaceutical excipient microcrystalline cellulose USP/NF.
- 35 C. Same as Example 2.A. above except the alkaline substance is pharmaceutical excipient lactose, anhydrous USP.

-17-

- D. Same as Example 2.A. above except the alkaline substance is pharmaceutical excipient maltodextrin.
- 5 E. Same as Example 2.A. above except the alkaline substance is Calcium Carbonate 90A (same as Example 1.C. above).
- 10 F. Same as Example 2.A. above except the alkaline substance is Calcium Carbonate granules (same as Example 1.B. above).
- 15 G. Same as Example 2.A. above except the alkaline substance is Sodium carboxymethylcellulose.

### Example 3.

#### Encapsulation:

20 The individual core granulation was mixed with 2% to 5% talc used as a lubricant, and then quantitatively encapsulated in hard gelatin capsules by known pharmaceutical techniques.

25

### Example 4.

#### Direct Tablet Compression:

30

- A. The individual core granulation was mixed with Lactose and Talc or magnesium stearate, and compressed into tablets by known pharmaceutical techniques.

-18-

## Example 5.

Capsule Enteric Coating:

5 The hard gelatine capsules obtained from Example 3. above were enteric coated in a conventional film coating machine with the following coating solutions by known pharmaceutical techniques.

10 Eudragit L-100 <sup>®</sup> (Methacrylic Acid Copolymer) 600 Grams  
Isopropyl Alcohol 8,600 Grams  
Triethyl Citrate 60 Grams  
FD&C or D&C aluminum laks 300 Grams  
Purified water 400 Grams

15

## Example 6.

A. Tablet Protective Coating:

20

The tablets obtained from Example 4. were coated in a conventional film coating machine with the following coating solution by known pharmaceutical techniques.

25 Methocel E15 <sup>®</sup> (Hydroxypropylmethylcellulose) 500 Grams  
Polyethylene Glycol E400 110 Grams  
Ethyl Alcohol 10,000 Grams

B. Enteric Coating for Tablets:

30

The coated tablets obtained from Example 6.A. were enteric coated in a conventional film coating machine with the coating solution being the same as that used in Example 5. by a known pharmaceutical technique.

35

-19-

## Example 7.

Coated Tablet in a Capsule:

- 5      The coated tablets obtained from Example 6.B. were encapsulated in empty hard gelatin capsules to form a capsule product.

## 10                      Example 8.

- 15      Several formulations were placed in ambient room temperature conditions for stability studies. The color changes of the core granulations were observed. Some of the formulations are assayed using USP High Pressure Liquid Chromatographic (HPLC) methods to determine the amount of drug remaining. The results are shown on Table 1. below.

-20-

Table 1.

Example	Stabliity Time Period	Color	% o f
Omeprazole			
Number	(Months)	Change	Remaining
1.A.	26	+	N/A
1.B.	26	0 to +	99.8
1.C.	26	0 to +	65.1
1.D.	26	0 to +	96.3
1.E.	11	+++	N/A
2.A.	13	0	89.6
2.B.	13	0	N/A
2.C.	11	+	91.0
2.D.	11	++	88.2
2.E. +3	11	0 to +	33.6
2.F. +3	11	0 to +	97.8
2.G.	11	0	96.2
2.C. +4	11	0 to +	N/A
2.F. +3+5	11	0 to +	96.4
2.F +6+7	11	0 to +	95.5

0 = no change

+ = intensity of color change

N/A no assay was performed

-21-

What is claimed is:

1. An improved pharmaceutical dosage form for oral  
administration to human being or animal host  
5 containing an acid-unstable drug active ingredient  
which comprises:
  - (a) a core granulation formed by dry mixing drug or  
its salt with alkaline substance and  
pharmaceutical excipient or excipients which can  
10 be quantitatively filled into an empty hard  
gelatin capsule shell;
  - (b) this hard gelatine capsule shell which  
constitutes simultaneously a separated barrier  
between the said core granulation and further  
15 processed outer enteric coating of said capsule  
during the completion of dosage form; and
  - (c) an enteric coating disposed on said capsule to  
prevent the capsule dosage form from releasing  
the acid-unstable drug or its salt in the gastric  
20 environment and to deliver it in the intestinal  
environment.
2. An improved pharmaceutical dosage form for oral  
administration to human being or animal host  
25 containing an acid-unstable drug active ingredient  
which comprises:
  - (a) a core tablet formed by dry mixing drug or its  
salt with alkaline substance, pharmaceutical  
excipient or excipients and directly compressing,  
30 which can be filled into an empty hard gelatin  
capsule shell;
  - (b) this hard gelatin capsule shell which constitutes  
simultaneously a separated barrier between the  
said core tablet and further processed outer  
35 enteric coating of said capsule during the  
completion of dosage form; and
  - (c) an enteric coating disposed on said capsule to

-22-

protect the capsule dosage form from releasing the acid-unstable drug or its salt in the gastric environment and to deliver it in the intestinal environment.

5

3. An improved pharmaceutical dosage form for oral administration to human being or animal host containing an acid-unstable drug active ingredient which comprises:

10

- (a) a core tablet formed by dry mixing drug or its salt with alkaline substance and pharmaceutical excipient or excipients and directly compressing, which can be coated with a protective layer as a barrier to:

15

- (i) separate the acid-unstable active drug in the core from the outer enteric coating; and

- (ii) protect the entered coating from the permeation of alkaline solution formed by water in the core tablet; and

20

- (b) an enteric coating disposed on said protectively coated tablet to protect it from releasing the acid-unstable drug in the stomach and to deliver the active to the small intestine.

25

4. An improved pharmaceutical dosage form for oral administration to human being or animal host containing an acid-unstable drug active ingredient which comprises:

30

- (a) a core tablet formed by dry mixing drug or its salt with alkaline substance and pharmaceutical excipient or excipients and directly compressing, which can then be coated with a protective layer as a barrier to:

35

- (i) separate the acid-unstable active drug in the core from the outer enteric coating; and



-23-

- (ii) protect the enteric coating from the permeation of alkaline solution formed by water in the core tablet;
- (b) an enteric coating disposed on said protectively coated tablet to prevent it from releasing the acid-unstable drug in the stomach and to deliver the active to the small intestine; and
- (c) this tablet is then filled into an empty hard gelatine capsule shell to form a final dosage form.
- 5.
- The dosage form according to claim 1 or 2 or 3 or 4 wherein the drug active ingredient is selected from the group consisting of omeprazole, sodium omeprazole, potassium omeprazole, calcium omeprazole, ammonium omeprazole, lansoprazole and pharmaceutical salt of lansoprazole.
- 6.
- The dosage form according to claim 1 or 2 or 3 or 4 wherein the alkaline substance is selected from one or any combination of the group consisting of alkaline metallic salt of carbonic acid, calcium carbonate, granulated calcium carbonate, dicalcium phosphate anhydrous, dibasic sodium phosphate anhydrous, tricalcium phosphate anhydrous, sodium carboxymethylcellulose, calcium carbosymethylcellulose, magnesium aluminum silicate, sodium lauryl sulfate and sodium bicarbonate.
- 7.
- The dosage form according to claim 2 or 3 or 4 wherein the pharmaceutical excipient is selected from one, or any combination of the group consisting of dextrose, sorbitol, mannitol, starch, dextrin, maltodextrin, lactose, magnesium stearate, calcium stearate, talc, microcrystalline cellulose, hydroxypropylmethylcellulose or hydroxyethylcellulose.

-24-

8. A dosage form according to claim 1 or 2 or 3 or 4 wherein the enteric coating comprises:
- 5 (a) enteric polymer selected from the group consisting of cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropyl methylcellulose acetate succinate, hydroxypropyl methylcellulose phthalate, polyvinyl acetate phythalate, anionic polymers based on methacrylic acid and methacrylic acid esters;
  - 10 (b) organic solvent selected from the group consisting of isopropyl alcohol, methanol, ethanol and ethyl acetate; to make polymer solution and aqueous system to make aqueous dispersion of polymer; and
  - 15 (c) plasticizer selected from the group consisting of triethyl citrate, polyethylene glycol 6000 and glycerol monostearate.
9. The dosage form according to claim 3 or 4 wherein the protective coating comprises:
- 20 (a) non-ionic protective polymer selected from the group consisting of hydroxypropyl methylcellulose, hydroxyethyl cellulose, and hydroxypropyl cellulose polyvinylpyrrolidone.
  - 25 (b) organic solvent selected from the group consisting of isopropyl alcohol, methanol and ethanol; and
  - 30 (c) plasticizer selected from the group consisting of triethyl citrate, propylene glycol and polyethylene glycol 6000.
10. A process for manufacturing the improved pharmaceutical dosage form of claim 1 comprises:
- 35 (a) preparing the core granulation by dry mixing the drug active ingredient with alkaline substance or by granulating with organic solvent the said mixture and drying;

-25-

- (b) filling the said dried core granulation into an empty hard gelatin capsule shell; and
- (c) coating the said capsule with an enteric coating solution or dispersion.

5

11. A process for manufacturing the improved pharmaceutical dosage form of claim 2 comprises:

- (a) preparing the core granulation by dry mixing the drug active ingredient with alkaline substance and pharmaceutical excipients;
- (b) directly compressing the said core granulation into tablets;
- (c) filling the said tablet into an empty hard gelatin capsule shell; and
- (d) coating the said capsule with an enteric coating solution or dispersion.

10

15

20

25

12. A process for manufacturing the improved pharmaceutical dosage form of claim 3 comprises preparing the core granulation by dry mixing, direct tablet compressing, subcoating the tablet with organic solvent base protective coating; and coating the subcoated tablets with an enteric coating solution or dispersion.

30

13. A process for manufacturing the improved pharmaceutical dosage form of claim 4 comprises preparing the core granulation by dry mixing, direct tablet compressing, subcoating the tablet with organic solvent base protective coating, coating the subcoated tablets with an enteric coating solution or dispersion, and filling the said enteric coated tablet into an empty hard gelatine capsule.

35

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US98/09449

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> IPC(6) :A61K 9/40, 9/14, 9/48, 9/52, 9/62 US CL :424/463 According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. FIELDS SEARCHED</b> Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/463, 478, 474, 484, 488  Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched  Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 95/01783 A1 (ASTRA AKTIEBOLAG) 19 JANUARY 1995 See entire document.	1-13
A	US 4,910,021 A (DAVIS ET AL) 20 MARCH 1990, see entire document.	1-13
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* *A* *E* *L* *O* *P*	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance earlier document published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	*T* *X* *Y* *A* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
Date of the actual completion of the international search 29 MAY 1998		Date of mailing of the international search report 0. 8 JUL 1998
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230		Authorized officer <i>B. K. Seidleck</i> BRIAN K. SEIDLECK Telephone No. (703) 308-1235